RxDoctor Payments Data

Kelley Scott, MD

Internal Medicine · Emeryville, CANPI 1477972438

Payments from drug & device makers

$1,238in general payments, 2019–2025

Across 48 payments — averaging $25.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$224
  • Merz North America, Inc.$213
  • Novo Nordisk$153
  • Boehringer Ingelheim$128
  • Abbott$110
  • Lilly USA, LLC$66
  • plus $344 from 13 others

What the payments were for

  • Food & beverage$1,238100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,238 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$143,469
Medicare patients
453
Services billed
1,449

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide33$43,852
XareltoRivaroxaban21$28,337
EliquisApixaban21$26,628
FarxigaDapagliflozin Propanediol26$23,760
PremarinEstrogens, Conjugated11$5,206
Wixela InhubFluticasone Propion/Salmeterol19$4,437
Estradiol48$3,951
Potassium Chloride27$3,626
Levothyroxine Sodium201$3,522
Atorvastatin Calcium262$3,163
Diltiazem 24hr Er (Cd)Diltiazem Hcl36$2,453
ValacyclovirValacyclovir Hcl31$2,335
Gabapentin78$2,061
Rosuvastatin Calcium125$2,043
Metoprolol Succinate86$1,961

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$153$43,85233 claims
PfizerEliquis, Premarin$31$31,83432 claims
AbbVieSynthroid$224$1,94218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Emeryville

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →